Iminosugar-Based Inhibitors of Glucosylceramide Synthase Increase Brain Glycosphingolipids and Survival in a Mouse Model of Sandhoff Disease

• Karen M. Ashe,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Dinesh Bangari,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Lingyun Li,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Mario A. Cabrera-Salazar,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Scott D. Bercury,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Jennifer B. Nietupski,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Christopher G. F. Cooper,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Johannes M. F. G. Aerts,

  Affiliation Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

  ⨯
• Edward R. Lee,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Diane P. Copeland,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Seng H. Cheng,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• Ronald K. Scheule,

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯
• John Marshall

  * E-mail: john.marshall@genzyme.com

  Affiliation Genzyme Corporation, Framingham, Massachusetts, United States of America

  ⨯